Earnings
-
Courtesy of Beta Bionics
Newly public Beta Bionics reports sales surge; Dexcom hires CCO
Sales of Beta Bionics insulin pumps spiked 145% in the fourth quarter behind solid new patient starts. Elsewhere, former Masimo exec Jon Coleman joined Dexcom, and Sibionics’ CGM earned the CE mark.
By Nick Paul Taylor • March 28, 2025 -
Courtesy of Hinge Health
Hinge Health, a virtual physical therapy firm, files for IPO
The digital health IPO market has slowed to a crawl in recent years, but experts say it could be poised for a turnaround in 2025.
By Emily Olsen • March 13, 2025 -
Courtesy of Elekta
Elekta CEO Gustaf Salford to leave after board sees need for new leader
Laurent Leksell, Elekta’s chairman of the board, said the company needs “new leadership that can further intensify the focus on improving profitability and strengthen growth.”
By Nick Paul Taylor • Feb. 27, 2025 -
Tim Boyle via Getty Images
After tough year, Baxter looks for next CEO to drive growth
Interim CEO Brent Shafer said the medical products maker is ready to begin a new era after several years of “heavy lifting” to simplify the business structure.
By Susan Kelly • Feb. 21, 2025 -
Patrik Stollarz / Staff via Getty Images
Philips expects sales struggles in China to continue in 2025
Philips forecast a double-digit sales decline in China for the first half of 2025 after reporting “significant deterioration” of demand in October.
By Nick Paul Taylor • Feb. 19, 2025 -
Courtesy of Medtronic
Medtronic nears FDA submission for Hugo robot
CEO Geoff Martha said Medtronic would submit its application for urological procedures to the Food and Drug Administration by the end of March.
By Ricky Zipp • Feb. 18, 2025 -
Courtesy of Edwards Lifesciences
Edwards predicts second-half lift from TAVR label expansion
Executives expect a new label indication and a hoped-for easing of hospital capacity constraints to accelerate sales this year.
By Susan Kelly • Feb. 12, 2025 -
Courtesy of Inspire Medical Systems
Inspire Medical reveals DOJ civil investigation
CEO Tim Herbert told investors the company received a civil investigative demand from the Department of Justice in January for information on marketing and reimbursement practices.
By Ricky Zipp • Feb. 11, 2025 -
Wirestock via Getty Images
Mass General Brigham to conduct largest layoffs in its history
MGB said the layoffs were necessary to get ahead of an anticipated budget shortfall of $250 million over the next two years.
By Susanna Vogel • Feb. 11, 2025 -
Spencer Platt via Getty Images
M&A and a separation take center stage in latest earnings season
BD announced it would split from its biosciences and diagnostics unit, while Zimmer Biomet updated investors on its $1.1 billion buy of Paragon 28.
By Susan Kelly • Feb. 10, 2025 -
Permission granted by Zimmer Biomet
Zimmer touts ASC opportunity with Paragon 28 purchase
With the $1.1 billion acquisition, Zimmer Biomet expects its sports medicine, extremities and trauma segment will outpace hips and knees.
By Elise Reuter • Feb. 6, 2025 -
Courtesy of Boston Scientific
Boston Scientific closes its year of PFA on a high note
Farapulse, Boston Scientific’s pulsed field ablation product, fueled year-over-year growth of nearly 171% in the fourth quarter for the company’s electrophysiology group.
By Ricky Zipp • Feb. 5, 2025 -
Justin Sullivan via Getty Images
23andMe considers sale as cash runs low
The genetic testing company ended last year with $79.4 million and told investors it will need to raise money to fund its operations and financial commitments.
By Nick Paul Taylor • Jan. 30, 2025 -
Courtesy of Getinge
Getinge exits surgical perfusion, creating opportunity for Livanova
Getinge CEO Mattias Perjos said surgical perfusion has “been a struggling category” since an FDA consent decree forced the company off the U.S. market in 2015.
By Nick Paul Taylor • Jan. 30, 2025 -
HadelProductions via Getty Images
Stryker to sell spinal implants business
The company named a new CFO and shared an update on its planned Inari Medical acquisition.
By Elise Reuter • Jan. 29, 2025 -
Courtesy of Intuitive
Trump tariffsIntuitive execs cast wary eye on potential Trump tariffs
The surgical robot leader is watching developments under the new administration but has not included any tariff impact in its financial forecast.
By Susan Kelly • Jan. 24, 2025 -
Permission granted by Abbott
Abbott expects to launch first PFA device outside of the US this year
CEO Robert Ford also plans to expand sales of the company’s Lingo over-the-counter glucose sensors after a limited rollout.
By Elise Reuter • Jan. 22, 2025 -
Permission granted by Johnson & Johnson
J&J coordinating with FDA on US pause of Varipulse due to safety risks
Johnson & Johnson executives, on a Wednesday earnings call, did not provide a timeline for when U.S. Varipulse cases will restart after halting procedures in early January.
By Ricky Zipp • Jan. 22, 2025 -
Justin Sullivan via Getty Images
Trump’s return to office brings uncertainty for medtech industry
With about one month before inauguration day, check out a roundup of MedTech Dive’s coverage on what President-elect Donald Trump’s new administration means for medical device companies.
By Ricky Zipp • Dec. 18, 2024 -
Bruce Bennett via Getty Images
Henry Schein to acquire medical supplier Acentus
Acentus, which specializes in supplying glucose sensors to patients’ homes, continues Henry Schein’s recent focus on building its homecare medical supplies business.
By Ricky Zipp • Nov. 21, 2024 -
Courtesy of Medtronic
Medtronic’s ablation sales slowed by PFA supply issues
CEO Geoff Martha said the business did not meet internal growth expectations last quarter due to third-party supply issues that have now been resolved.
By Ricky Zipp • Nov. 19, 2024 -
Courtesy of Boston Scientific
Boston Scientific closes $3.7B Axonics deal after lengthy review
Boston Scientific announced the acquisition in January, but the review dragged on after the Federal Trade Commission requested more information.
By Ricky Zipp • Nov. 15, 2024 -
Kimberly White/Getty Images via Getty Images
23andMe to lay off more than 200 employees amid business struggles
The genetic testing firm will also close its therapeutics arm. CEO Anne Wojcicki said the cuts are necessary to “focus on the long-term success of our core consumer business.”
By Ricky Zipp • Nov. 13, 2024 -
Retrieved from Aerial Lens on October 10, 2024
Baxter to restart second IV fluid production line at hurricane-damaged site
CFO Joel Grade told investors Friday that Baxter expects an approximately $200 million hit to sales in the fourth quarter from Hurricane Helene's disruption.
By Susan Kelly • Nov. 11, 2024 -
Courtesy of Exact Sciences
Exact Sciences’ forecast cut shocks analysts
The lowered sales forecast, which analysts called a “shocking guidance update,” contributed to a 23% drop in the cancer screening company’s stock on Wednesday.
By Nick Paul Taylor • Nov. 8, 2024
